Gene therapy for stiff heart failure (preserved EF)
Part of Heart & circulation clinical trials.
This trial tests a one-time gene therapy for people with heart failure who still have normal pumping strength (preserved ejection fraction). It aims to improve how heart cells handle calcium, which may help the heart relax better and ease symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure with preserved ejection fraction (your heart pumps well but is stiff).
- You are in New York Heart Association class II or III (mild to moderate symptoms like shortness of breath on activity).
- Your left ventricular ejection fraction (how much blood your heart pumps out) is 50% or higher.
- You must have high filling pressure in your heart (shown by your doctor) and be taking a water pill (diuretic).
- You must not have certain other heart conditions, like atrial fibrillation, blocked arteries, or recent heart failure hospitalization.
- You must not have active cancer (within 5 years), severe lung disease, or be very overweight (BMI over 50).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy injected into the heart to help it recover after a previous heart attack. It may be an option for people with stable heart failure who are not eligible for standard procedures like stents or bypass surgery.
This trial tests a gene therapy that may help rebuild muscle and improve blood vessel growth in people ages 35 to 75. It's designed for those with stable health conditions and no history of cancer, heart disease, blood clots, or diabetes.
This trial tests a one-time gene therapy that delivers a corrected copy of the frataxin gene directly to the heart. It aims to improve or stabilize heart function in people with Friedreich's ataxia who have early or advanced heart involvement.
This trial tests an experimental gene therapy (AFTX-201) designed to address the genetic cause of heart failure in people with a specific BAG3 gene mutation. It aims to improve heart function and reduce symptoms.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This trial tests a one-time gene therapy called LX2006 for heart problems caused by Friedreich ataxia. The goal is to see if it can improve heart function and structure.
Hear when a new Heart Failure, Diastolic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.